Taiho pharmaceutical exercises option for an exclusive license to arcus biosciences' anti-tigit program in japan and certain territories in asia

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, and taiho pharmaceutical co., ltd., (“taiho”), an r&d driven specialty pharma company with a focus on oncology, today announced that taiho exercised its option for anti-tigit antibodies domvanalimab (development code: ab154) and ab308 from arcus biosciences (“arcus”), in japa
RCUS Ratings Summary
RCUS Quant Ranking